Filing Details

Accession Number:
0001484612-22-000054
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-06-02 16:30:01
Reporting Period:
2022-06-01
Accepted Time:
2022-06-02 16:30:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1484612 Outset Medical Inc. OM Electromedical & Electrotherapeutic Apparatus (3845) 200514392
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1823380 Martin Vazquez 3052 Orchard Drive
San Jose CA 95134
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-06-01 5,000 $3.88 54,237 No 4 M Direct
Common Stock Disposition 2022-06-01 5,000 $21.42 49,237 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Performance Options (right to buy) Disposition 2022-06-01 5,000 $0.00 5,000 $3.88
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
108,007 2027-12-19 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2022.
  2. The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from: $20.00-$21.99 - 509 shares; $21.00-$22.99 - 4,286 shares; $23.00-$23.99 - 205 shares. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. In March 2021, following the expiration of the lock-up period in connection with our initial public offering, the applicable performance and market-based vesting conditions were met and the shares underlying this stock option award became fully vested.